SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending following news that Martin Shkreli has taken a position in the company and set a near-term price target of $100, sparking considerable discussion among investors. The community is actively discussing the potential of the company's technology and the implications of Shkreli's involvement, with some expressing skepticism and others anticipating a significant price increase. High trading volume and recent price action suggest heightened interest in QCLS within the next-generation computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions of its earnings report, where annualized recurring revenue increased, and the CEO highlighted the company's AI automation strategy. The community is focused on the potential for a short squeeze and positive long-term outlook, with some discussing potential price targets for 2026. Recent partnerships and analyst ratings are also key talking points.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing a surge in interest, with community members attributing the recent price action to upcoming satellite launches and potential government contracts. Community members are actively discussing technical analysis points, institutional investment, and the potential for ASTS to disrupt the telecom industry. Some traders express caution, referencing the company's history of missed deadlines and the broader economic climate.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid discussions around its recent earnings and future guidance, with community members debating the impact of AI integration and overall market sentiment. Some traders are focusing on potential long-term value while others express concern over the company's performance relative to its peers. The stock's volatile price action and upcoming earnings are also fueling active conversations.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential for a buyout or strategic partnership, fueled by promising data in lung, prostate, and pancreatic cancers. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. The discussion is around CADL's pipeline and proximity to BLA filing, which could increase its attractiveness in the biotech sector.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around competing bids from Netflix, Paramount, and Comcast to acquire the media giant. Community chatter highlights the potential for a bidding war, with some believing a deal could be reached soon, while others discuss the implications of each potential suitor. Discussions also include potential impacts on shareholders, debt considerations, and regulatory hurdles.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community anticipates upcoming catalysts, including a Type B meeting with the FDA on December 15th regarding its lead drug candidate, sonelokimab (SLK).  Optimism stems from the drug's potential in treating inflammatory and autoimmune diseases, as well as speculation around a possible buyout from a major pharmaceutical company.  Despite recent clinical trial setbacks and shareholder lawsuits, investors are closely watching for positive news that could significantly impact the stock's valuation.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending amid a mix of bullish analyst upgrades and some community concern regarding slower product revenue growth forecasts. Some traders are pointing to insider selling and margin shrinkage as reasons to be bearish, while others see recent partnerships with Palantir and Anthropic, and growing AI adoption, as positive catalysts. Overall, the discussion revolves around valuation and whether Snowflake can maintain its high growth trajectory.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

AI is trending due to a U.S. Department of Health and Human Services contract win, with community members seeing this as a potential catalyst for a short squeeze given the stock's high short interest. Bullish sentiment is building around the new CEO and potential for government deals, while some are comparing it unfavorably to competitors and citing concerns around revenue and profitability. Overall, the conversation is centered on whether this news can spark a turnaround for the heavily shorted AI stock.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to its subsidiary Less Common Metals' supply agreement with Solvay and Arnold Magnetic Technologies. This deal is fueling discussions about US independence in rare earth metals and potential government backing. Community members are actively debating the stock's potential and comparing it to sector peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Brokerages

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have earned a consensus recommendation of "Hold" from the five ratings firms that are covering the firm, MarketBeat.com reports. One...

Los Angeles Capital Management LLC Has $284,000 Stake in Coherus Oncology, Inc. $CHRS

Los Angeles Capital Management LLC reduced its position in Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) by 60.9% in the 2nd quarter, according to the company in its most recent disclosure with...

Coherus Oncology (NASDAQ:CHRS) Raised to Hold at Wall Street Zen

Wall Street Zen raised shares of Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results

Coherus Oncology (NASDAQ:CHRS - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.33) earnings per share for the quarter, topping analysts' consensus...

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Current Price	$1.24
Prev Close	$1.22
Open	$1.21
Dividend Yield	0.00%
50-Day Moving Average	$1.51
Beta	1.77
Avg. Volume	1.42M
PE Ratio	-0.77

52-Week High	$1.89
52-Week Low	$0.71
Market Capitalization	$147.46M
EPS (Annual)	$0.2482
Price to Book	1.62
Revenue Per Employee	$1.17M
Enterprise Value/EBITDA	N/A

CHRS
Coherus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CHRS News

CHRSCoherus Biosciences Inc